Expert Insight: How to streamline development of a cytotoxicity assay for high-content compound screening
Watch this on demand webinar to learn how to speed up your assay development process
17 Mar 2021
Christian Oberdanner, Tecan Austria and Dr. Christopher Wolff, FMP Berlin
High-content screening and morphological profiling is becoming increasingly popular in the characterization of new compounds and their mode of action in pharmaceutical and academic drug development. Using highly sensitive technologies, morphological changes can already be detected in sub-cytotoxic concentrations. For the generation of morphological profiles, a precise investigation of cytotoxicity with respect to concentration and time is therefore indispensable.
In this on-demand webinar, Dr. Christopher Wolff, FMP Berlin, presents a fast and reliable method to develop a cytotoxicity assay for high-content screening (HCS) using Tecan’s Spark